Physician profile
Mark A Gibson
NPI 1992744155
$1,871.23
in general payments reported to CMS, 2019-2025
19 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.49 · 2020: $45.15 · 2021: $32.03 · 2022: $46.64 · 2023: $442 · 2024: $721 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $313.71 | 2020-2024 | Cardiomems, Jot Dx, Assurity |
| Pfizer INC. | $231.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $220.75 | 2019-2025 | |
| Edwards Lifesciences Corporation | $166.33 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia, Pascal |
| Alnylam Pharmaceuticals INC. | $145.20 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $142.83 | 2023-2024 | |
| Amgen INC. | $137.26 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $135.90 | 2022-2025 | Watchman Flx, Bodyguardian |
| Merck Sharp & Dohme LLC | $123.08 | 2023-2025 | Verquvo |
| Esperion Therapeutics, INC. | $67.25 | 2021-2024 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.58 | 2024-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $31.53 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $22.59 | 2025 | Opsumit, Uptravi |
| Janssen Biotech, INC. | $19.49 | 2025 | Simponi, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $17.07 | 2024 | Eliquis |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $16.17 | 2023 | Barostim Neo System |
| Kiniksa Pharmaceuticals, LTD. | $16.11 | 2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.48 | 2025 | Jardiance |
| Medtronic Vascular, INC. | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.